Kadmon Leadership

Dr. Harlan Waksal is President and Chief Executive Officer at Kadmon. Dr. Waksal is Co-Founder of ImClone Systems (sold to Eli Lilly & Company in 2008 for $6.5 billion). At ImClone, Dr. Waksal co-led a pioneering effort in the development of biologics targeting tyrosine kinase receptors. This work resulted in the development and U.S. Food and Drug Administration (FDA) approval of Erbitux® (cetuximab), one of the top-selling cancer drugs in the world. In addition, efforts at ImClone led to the development of Cyramza® (ramucirumab), FDA approved in 2014 for the treatment of gastric cancer and non-small cell lung cancer, as well as a number of other product candidates currently in clinical development. Dr. Waksal served in senior roles at ImClone as follows: President (March 1987 to April 1994); Executive Vice President and Chief Operating Officer (April 1994 to May 2002); and President, Chief Executive Officer and Chief Operating Officer (May 2002 to July 2003). Dr. Waksal also served as a Director of ImClone from March 1987 to January 2005.

Bar Admissions:New York, United States of America, SDNY, SCOTUSNew South Wales, Australia, High Court of Australia

Entrepreneurial expertise in strategic growth and product uptake for leading pharmaceutical and medical device companies. Highly competitive, passionate, persuasive and articulate, able to achieve results others believed to be impossible. Highly experienced in marketing, new product development, commercial partnership building, and product management. Proven ability to build successful entry positions for either device or pharmaceutical portfolios through innovative marketing strategies and team leadership.

 Strategic Thinking in Commercial Pharmaceutical Business

 New Business Development

 Product Launch Platforms

 Launch Readiness

 Business Planning

 Leading Multi-Specialty Teams

 Strategic Collaboration

 Clinical and Marketing Expertise

 Professional Education

 Entrepreneurial Thinking and Experience

Michael J. Howerton is a Chief Operating and Financial Officer and Executive Vice President at KADMON HOLDINGS, INC..

Peter has worked in Life Sciences for over 18 years, in all aspects of IT and digital marketing. He has lead multiple, large organizational change initiatives, vision alignments and other strategic leadership projects across a global enterprise. He is experienced in leading an IT organization across the entire Life Sciences value chain, from R&D and clinical operations to the commercialization of product. He has experience working in large, mature multi-national pharma companies and also at small biotech startups. He is entrepreneurial and relentless in achieving goals.

His accomplishments include:

+ digitizing clinical operations and regulatory in less than two years

+ preparing a digital marketing strategy for a company's first commercial launch

+ establishing an enterprise architecture practice, a project portfolio management office (PMO), and an IT relationship management role

+ defining a roadmap and vision for a new, customer-centric marketing model

+ creating a centralized dashboard of all digital promotion marketing channels across five brands

+ optimizing multiple core business processes, yielding the company millions of dollars in ROI

+ developing a global sourcing and staffing strategy for the entire IT function

+ leading annual IT strategic budget planning for four years

Simon Cooper is a Senior VP/Chief Medical Officer at KADMON HOLDINGS, INC. and is based in Cambridge, Massachusetts. He has worked as Director Inflammation and Autoimmunity at Medimmune, VP/Head:Global Projects at SANOFI, and Group Project Leader at AbbVie. Simon studied at NEWCASTLE UNIVERSITY between 1988 and 1993.

Stephen Meehan is an Australian professional rugby union football coach. He is currently an assistant coach at Toulon in the Top 14 competition in France, and was formerly in charge of Bath Rugby in the English Premiership. He was head coach of the Queensland Country team for the inaugural season of Australia's National Rugby Championship in 2014.

Dr. Harlan Waksal is President and Chief Executive Officer at Kadmon. Dr. Waksal is Co-Founder of ImClone Systems (sold to Eli Lilly & Company in 2008 for $6.5 billion). At ImClone, Dr. Waksal co-led a pioneering effort in the development of biologics targeting tyrosine kinase receptors. This work resulted in the development and U.S. Food and Drug Administration (FDA) approval of Erbitux® (cetuximab), one of the top-selling cancer drugs in the world. In addition, efforts at ImClone led to the development of Cyramza® (ramucirumab), FDA approved in 2014 for the treatment of gastric cancer and non-small cell lung cancer, as well as a number of other product candidates currently in clinical development. Dr. Waksal served in senior roles at ImClone as follows: President (March 1987 to April 1994); Executive Vice President and Chief Operating Officer (April 1994 to May 2002); and President, Chief Executive Officer and Chief Operating Officer (May 2002 to July 2003). Dr. Waksal also served as a Director of ImClone from March 1987 to January 2005.